3 research outputs found
Examining international practices in the management of pregnant women with von Willebrand disease
Background: The management of pregnant women with von Willebrand disease (VWD) is complex as physiological pregnancy-induced increases in plasma von Willebrand factor (VWF) may be blunted or absent. Women with VWD experience a heightened risk of postpartum hemorrhage (PPH) and special consideration must be given regarding neuraxial anesthesia (NA) and the need for prophylaxis at time of delivery. These challenges are compounded by a lack of robust evidence to guide clinical decision-making.
Objectives and methods: To determine the current international clinical practices in the management of pregnancy for women with VWD, the International Society on Thrombosis and Haemostasis (ISTH) conducted an international survey of health-care providers (HCP).
Results: One hundred thirty-two respondents from 39 countries were included in the final analysis. Variations in clinical practice were identified in antenatal (monitoring of plasma VWF and ferritin levels), peripartum (optimal plasma VWF target at delivery) and postpartum management (definitions used for PPH and postpartum monitoring). A key area of divergence was suitability for NA for women with type 2 and type 3 VWD, with many respondents advising against the use of NA even with VWF supplementation (29% type 2 VWD, 37% type 3 VWD) but others advising use once plasma VWF activity was >50 IU/dL (57% type 2 VWD; 50% type 3 VWD).
Conclusions: This survey highlighted areas of uncertainty surrounding common management issues for pregnant women with VWD. These data underscore the need for international collaborative research efforts focused on peripartum management to improve care for pregnant women with VWD.</div
Supplementary_Material – Supplemental material for Prospective analysis of bleeding events in left ventricular assist device patients
<p>Supplemental material, Supplementary_Material for Prospective analysis of bleeding events in left ventricular assist device patients by Saadia Sherazi, Peter Kouides, Charles Francis, Charles Julian Lowenstein, Majed Refaai, Grace Conley, Brent Alan Johnson, Eugene Muchnik, Susan Lien, Howard Todd Massey and Jeffrey Dean Alexis in The International Journal of Artificial Organs</p
von Willebrand disease: proposing definitions for future research
von Willebrand disease (VWD) is a common bleeding disorder, which affects 1 in 100 individuals based
on laboratory testing and at least 1 in 1000 individuals based on presence of abnormal bleeding
symptoms.1,2 VWD was first described almost 100 years ago, and since the initial report, major
advances in both diagnostic testing and treatment options have improved outcomes for patients living
with VWD; however, many patients still experience significant complications and barriers to treatment.
An underlying problem is the lack of consistent unified definitions.
In recent work developing evidence-based guidelines for VWD,3,4 it was noted that studies on VWD
often used varying definitions. For example, studies of von Willebrand factor (VWF) concentrates did not
have consistent definitions for major bleeding, studies on VWF prophylaxis did not use consistent
definitions of what constituted a prophylaxis regimen, and studies on desmopressin did not use
consistent definitions of desmopressin responsiveness. In addition, common bleeding conditions,
such as heavy menstrual bleeding (HMB) and postpartum hemorrhage are variably defined. Such
inconsistencies in describing study regimens and endpoints hinder the ability to compare study
outcomes and to advance treatment of patients with VWD.
We propose definitions for future use in VWD research to facilitate comparison of treatment options.
These definitions are based on the most common usage in the literature and endeavor to encompass the
most common situations in VWD. The proposed definitions were derived from existing literature and
discussed at the first in-person meetings of the guideline panels. Group members made amendments,
and the consensus document was circulated to the group. All authors approved the final document